$RLX

RLX Technology Announces Unaudited Second Quarter 2026 Financial Results

RLX Technology (NYSE: RLX) reported unaudited Q2 2026 results for the quarter ended June 30, 2026. Net revenues rose 14.8% to RMB1,010.5 million (US$148.9 million). Gross margin increased to 35.4%. U.S. GAAP net income was RMB222.0 million. In July 2026, RLX acquired a 51% stake in a Western European distributor, consolidated starting Q3 2026.

Original reporting
Published Aug 14, 2026, 10:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 10:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RLX
Bullish
medium confidence
Mentioned
$RLX
Relevance
8/10
AlphAI data visualization · based on prnewswire.com
Decision brief

The 30-second read

$RLXBullishMed
01

Why it matters

The quarter shows stronger gross margin and operating income versus the prior year, while the acquisition with board control and consolidation beginning in Q3 is a tangible structural change.

02

Market read

Traders can reassess near-term earnings power based on margin expansion and operating income growth, and model Q3 consolidation effects from the new distributor stake.

03

What to watch

The text notes a prior-quarter one-time export regulation benefit and that revenues and gross profit moderated from Q1; traders may discount the quarter’s strength if normalization continues.

Relevance 8/10Novelty 7/10Timing: earnings release today, conference call scheduled 8:00 AM ET

Background

RLX Technology, a branded e-vapor company, released unaudited Q2 2026 financial results and described a July 2026 51% acquisition of a Western European smoke-free distributor.

Company-level read

Ticker impact

$RLXBullishMedium confidence
Context

RLX reported Q2 2026 results with net revenue up 14.8% YoY and gross margin rising to 35.4%, plus a July 2026 51% distributor acquisition.

Expected impact

Near-term bias positive on earnings quality and margin expansion; follow-through depends on whether Q3 consolidation and smoke-free expansion sustain margins.

Evidence & confidence

The release provides multiple quantified improvements (revenue, gross margin, operating income) and a concrete corporate action (51% acquisition with consolidation timing). However, it is unaudited and lacks forward guidance or explicit consensus comparison in the text.

Market effects

Improving margins and expansion into smoke-free categories may reinforce investor appetite for branded e-vapor and adjacent smokeless products.

International business is 68.5% of revenue, so results may influence sentiment toward RLX’s Europe and Asia distribution execution.

As a global branded e-vapor company, RLX’s profitability trend can marginally affect broader risk sentiment in the smokeless/e-vapor supply chain.

Counterpoint

Gross margin improvement may be mix- and supply-chain-driven rather than durable demand strength, and non-GAAP net income fell versus the prior year quarter.

Key entities

  • RLX Technology Inc.

    NYSE-listed branded e-vapor company reporting Q2 2026 results and a July 2026 51% distributor acquisition.

  • Western European distributor (acquired 51%)

    Distributor of next-generation smoke-free and FMCG products; RLX acquired 51% equity interest and board control, consolidating starting Q3 2026.

Related articles

$RLXMed

RLX Technology (RLX) Bets Big On Europe And Nicotine Pouches

RLX Technology (RLX) reported Q2 2026 revenue of RMB1.01B (+14.8% YoY), with international sales at 70% of revenue. Gross margin expanded to 35.4% due to supply chain and product mix improvements. The company acquired a 51% stake in a European distributor, aiming to build direct retail relationships. However, China revenue is expected to be flat for the year due to regulatory tightening. RLX is also investing in nicotine pouches and has RMB13.9B in capital resources.

$RLXMedAI 8/10

RLX Technology (RLX) Q2 2026 Earnings Call Transcript

RLX Technology reported Q2 2026 net revenue of RMB 1,010.5 million, up 14.8% YoY, driven by international expansion and a 2025 acquisition. Gross margin expanded to 35.4% from 27.5% YoY. International sales contributed 70% of revenue. Non-GAAP income from operations rose 28.8% YoY to RMB 149.6 million. GAAP net income increased 1.6% YoY to RMB 222.0 million. Management highlighted growth in oral nicotine pouches and a 51% investment in a European distributor.

$RLXMed

RLX Technology Inc. (RLX): Financial results for Q2 2026

RLX Technology Inc. (RLX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 RLX Technology Announces Unaudited Second Quarter 2026 Financial Results SHENZHEN, August 14, 2026 /PRNEWSWIRE/ - RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE: RLX), a leading global branded e-vapor company, today announced its unaudited financial re

$RLXMedAI 8/10

Robust Earnings and International Expansion Assert RLX Technology Inc. (RLX) as a Top Sin Stock to Buy

RLX Technology (NYSE:RLX) reported first-quarter results on May 20 that beat expectations, driven by international expansion. Net revenues rose 96.2% to $229.9 million and gross margin improved to 31.8% from 28.6%. Adjusted net income increased 41.4% to $51.8 million, with adjusted EPS of $0.038. International operations were 72.3% of revenue, led by Europe and Asia.

$IPHAMed

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

Innate Pharma (IPHA) reported Q2 2026 earnings, highlighting a cash position of -€21.4M, a $75M upfront payment from Sobi, and -€28M in net equity proceeds. H1 2026 net loss was -€19.6M, with revenue of -€5.7M. The company extended its cash runway to Q1 2028 and anticipates key milestones, including a Phase 3 readout for monalizumab and initial data for IPH4502. Management expects to file for accelerated approval of lacutamab in Sezary Syndrome in H2 2027.

$UPXIMed

Upexi Inc (UPXI) (Q4 2026) Earnings Call Highlights: Massive Solana Treasury Fuels $246

Upexi Inc. (UPXI) reported Q4 2026 earnings, highlighting a $246M net loss driven by digital asset losses. CEO Alan Marshall discussed Solana treasury management, debt restructuring, and cost-cutting efforts. The company holds 2.34M Solana tokens, with staking revenue covering expenses. Management emphasized creative capital allocation and potential expansion in Asian markets through the Hivemind partnership. Stockholders' equity was negative $53.8M as of June 30, 2026.